Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen and Chime Biologics today announced that they have entered into a manufacturing services agreement.

Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

Humanigen Inc (NASDAQ: HGEN) is prepping its COVID-19 drug lenzilumab for an emergency use authorization with the FDA before the month's end. According to its Q1 financial report out Thursday after-hours, the company said it had “recently held a meeting with FDA” to discuss the filing of a EUA for lenzilumab, specifically for hospitalized, hypoxic COVID-19 patients, “at the end of May.

Humanigen Shares Gain On FDA Emergency Filing Plans For COVID-19 Drug By June

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. today reported financial results for the first quarter ending March 31, 2021 and provided a regulatory update on lenzilumab.

Humanigen Reports First Quarter 2021 Financial Results

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock?

Humanigen Inc. (NASDAQ: HGEN) shares made gains Wednesday  following the publication of results from a Phase 3 randomized double-blind placebo-controlled study.

This Biotech Stock Could See A Big Move If It Breaks Out Of The Pennant It's Forming

Detailed results from a late-stage study of the company's lead candidate were published online.

Why Humanigen Stock Vaulted Higher Today

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, announced that results from the lenzilumab Phase 3 study in hospitalized COVID-19 patients (referred to as ‘LIVE-AIR') were published online at link. About Humanigen, Inc. Humanigen, Inc. is developing its portfolio of clinical and pre-clinical th

Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer.

Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer

Edgewise Therapeutics

They're both innovating in attractive areas where there's no competition on the radar.

2 Juicy Biotech Stocks to Consider Buying Right Now

Ocugen, Inc.

New coronavirus projects make them easy to hype, but they could face strong headwinds soon.

Reddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks

Humanigen Inc (NASDAQ: HGEN) has announced data from the Phase 1b portion of the ZUMA-19 trial evaluating its lead candidate lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL). ZUMA-19 study designed to evaluate the efficacy and safety of lenzilumab and CAR-T (axicabtagene ciloleucel, Axi-Cel).

Humanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study

BURLINGAME, Calif.--(BUSINESS WIRE)--Positive data announced from the Phase 1b portion of ZUMA-19 evaluating the efficacy and safety of lenzilumab in patients treated with CAR-T in DLBCL.

Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study

RedHill Biopharma

They're approaching the treatment-race finish line.

Could These 2 Exciting COVID Stocks be 10-Baggers?

Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer. The results will be presented as a poster at the AACR Annual Meeting 2021.

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive results from the Phase 1 safety and bioimaging trial of ifabotuzumab.

Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme

Could Humanigen Stock Soar Even Higher After Its COVID Antibody Results?

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it completed its underwritten public offering of common stock.

Humanigen Announces Closing of Public Offering of Common Stock

The company announced the pricing of a secondary stock offering.

Why Humanigen Stock Is Tanking Today

The stock price of Humanigen, Inc. (Nasdaq:HGEN) fell by over 10% pre-market. This is why it happened.

HGEN Stock Price Fell Over 10% Pre-Market: Why It Happened

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen of approximately $92.5 million, before deducting un

Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock

Humanigen Inc. (NASDAQ: HGEN) share rallied Monday amid positive Phase 3 data demonstrating Lenzilumab TM achieved its primary endpoint. The drug improves survival without the need for mechanical ventilation in hospitalized COVID-19 patients.

Humanigen Rallies 54%: A Technical Analysis

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock.

Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock

Shares of Humanigen skyrocketed as high as 107% to their highest since 2016 on Monday after the biopharmaceutical company revealed that its leading drug candidate met its goal of improving survival among COVID-19 patients without the need for mechanical ventilation in a late-stage trial. The Burlingame, California-company on Monday announced that patients who received lenzilumab, the drug candidate, and other treatments, including steroids and remdesivir, were 54% more likely to survive without the need for mechanical ventilation through day 28, compared with patients receiving placebo and other treatments.

Humanigen skyrockets 107% after results show its drug candidate improves COVID-19 survival in patients without a ventilator

The company's investigational coronavirus treatment could hit the market soon.

Why Humanigen Stock Is Skyrocketing Today

Shares of HGEN stock are soaring after the firm said its drug results show improved survival for Covid-19 patients without a ventilator. The post HGEN Stock: Why Covid-19 Play Humanigen Is Skyrocketing 100% Today appeared first on InvestorPlace.

News for Humanigen Stock (HGEN)